Equus Total Return, Inc. (NYSE:EQS) Short Interest Update

Equus Total Return, Inc. (NYSE:EQS) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 40,216 shares, a growth of 105.5% from the June 30th total of 19,567 shares. Based on an average daily trading volume, of 13,670 shares, the days-to-cover ratio is currently 2.9 days. Currently, 0.4% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Equus Total Return from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Equus Total Return Stock Performance

Equus Total Return stock opened at $1.16 on Friday. Equus Total Return has a 12-month low of $1.07 and a 12-month high of $2.49. The company has a market capitalization of $16.21 million, a price-to-earnings ratio of -1.07 and a beta of 0.15. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.77 and a quick ratio of 0.77. The firm’s fifty day moving average price is $1.26 and its 200 day moving average price is $1.37.

Equus Total Return Company Profile

Equus Total Return, Inc (NYSE:EQS) is a publicly registered, non-traded real estate investment trust (REIT) that focuses on acquiring, managing and repositioning income-producing commercial properties. The company seeks to generate long-term total returns through a combination of current income and capital appreciation by targeting corporate-leased office, industrial and retail assets with value-add potential. Equus Total Return operates with the flexibility to pursue core-plus and opportunistic investment strategies across multiple property types and markets.

The REIT’s portfolio spans major metropolitan regions across the United States, including dense urban markets along the East Coast, growth corridors in Texas and established industrial hubs in the Midwest and West Coast.